Other big issues include combating antibiotic resistance in the U.S., stemming the opioid epidemic that has quadrupled overdose deaths in the U.S. since 1999 and remaining vigilant
against the perennial onslaught of influenza — as well as
emerging threats including tick - borne
pathogens.
NIAID's biodefense research is integrated into its larger
emerging and re ‐
emerging infectious diseases portfolio that uses sophisticated genomic and proteomic platforms focused on developing broad ‐ spectrum therapies effective
against entire classes of
pathogens.